{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacodynamic&page=2", "query": { "condition": "Pharmacodynamic", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacodynamic&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T22:24:55.069Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05864144", "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Advanced Solid Tumor", "Head and Neck Cancer", "Breast Cancer", "Colon Cancer", "Pancreatic Cancer", "Gastric Cancer", "Esophageal Cancer", "Prostate Cancer", "Uterine Cancer", "Cervix Cancer", "Ovarian Cancer", "Kidney Cancer", "Bladder Cancer", "Thyroid Cancer", "Melanoma", "Sarcoma", "Advanced Cancer", "Metastatic Cancer", "Refractory Cancer", "Non Small Cell Lung Cancer", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "SNS-101 (anti-VISTA)", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sensei Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2023-05-31", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-07-23T22:24:55.069Z", "location_count": 10, "location_summary": "Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05864144" }, { "nct_id": "NCT00382798", "title": "Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy Volunteers", "Hepatitis C Virus" ], "interventions": [ { "name": "RO5024048", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmasset", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 75, "start_date": "2006-10", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2009-04-27", "last_synced_at": "2026-07-23T22:24:55.069Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00382798" }, { "nct_id": "NCT02450552", "title": "Clinical Trial of Ezogabine (Retigabine) in ALS Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "Ezogabine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brian Wainger", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 65, "start_date": "2015-06", "completion_date": "2018-02", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-07-23T22:24:55.069Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • Orange, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02450552" }, { "nct_id": "NCT01916863", "title": "Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "LX4211 400 mg", "type": "DRUG" }, { "name": "canagliflozin 300 mg", "type": "DRUG" }, { "name": "LX4211 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lexicon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 25, "start_date": "2013-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-30", "last_synced_at": "2026-07-23T22:24:55.069Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01916863" }, { "nct_id": "NCT05462106", "title": "A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Amyloid Plaque", "Beta-Amyloid", "DSAD", "Prodromal Alzheimer's Disease", "Alzheimer's Disease" ], "interventions": [ { "name": "Placebo (Study Part 1a)", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose A in Study Part 1a", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose B in Study Part 1a", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose C in Study Part 1a", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b", "type": "BIOLOGICAL" }, { "name": "Placebo (Study Part 2)", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose A in Study Part 2", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose B in Study Part 2", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose C in Study Part 2", "type": "BIOLOGICAL" }, { "name": "Placebo (Study Part 1b)", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AC Immune SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "35 Years to 85 Years" }, "enrollment_count": 304, "start_date": "2022-06-21", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-07-23T22:24:55.069Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lady Lake", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "The Villages", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462106" }, { "nct_id": "NCT00865904", "title": "Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-809", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2009-03", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2015-08-28", "last_synced_at": "2026-07-23T22:24:55.069Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00865904" }, { "nct_id": "NCT03305471", "title": "DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hyperphosphatemia" ], "interventions": [ { "name": "DS-2330b PIB", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sevelamer", "type": "DRUG" }, { "name": "DS-2330b Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 40, "start_date": "2017-08-17", "completion_date": "2019-01-03", "has_results": false, "last_update_posted_date": "2019-03-25", "last_synced_at": "2026-07-23T22:24:55.069Z", "location_count": 4, "location_summary": "Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more", "locations": [ { "city": "Lakewood", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03305471" }, { "nct_id": "NCT01919684", "title": "Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "LGD-6972", "type": "DRUG" }, { "name": "Placebo (Captisol®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ligand Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 56, "start_date": "2013-11", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2014-09-25", "last_synced_at": "2026-07-23T22:24:55.069Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01919684" }, { "nct_id": "NCT00002236", "title": "A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Delavirdine mesylate", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacia and Upjohn", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": null, "sex": "ALL", "summary": "14 Years and older" }, "enrollment_count": 32, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-07-23T22:24:55.069Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • New York, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002236" }, { "nct_id": "NCT01898364", "title": "Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pompe Disease", "Glycogen Storage Disease Type II (GSD II)", "Acid Maltase Deficiency" ], "interventions": [ { "name": "GZ402666", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2013-08-19", "completion_date": "2015-02-25", "has_results": false, "last_update_posted_date": "2023-03-23", "last_synced_at": "2026-07-23T22:24:55.069Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Kansas City, Kansas + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01898364" } ] }